Higher County-Level Prostate Cancer Screening Tied to Better Outcomes
By Lori Solomon HealthDay Reporter
FRIDAY, June 7, 2024 -- Higher county-level prevalence of prostate-specific antigen (PSA) screening is associated with lower odds of advanced disease, all-cause mortality, and prostate cancer-specific mortality, according to a study published online June 4 in JAMA Network Open.
Hari S. Iyer, Sc.D., from Rutgers Cancer Institute of New Jersey in New Brunswick, and colleagues examined whether county-level prevalence of PSA screening is associated with lower mortality among men with prostate cancer (2000 through 2015). Analysis included 814,987 men (aged 40 to 99 years) with prostate cancer followed up for up to 10 years through cancer registries in eight U.S. states.
The researchers found that men in the highest versus lowest quintile of county-level PSA screening prevalence at diagnosis had lower odds of advanced versus localized stage (adjusted odds ratio [aOR], 0.86), lower all-cause mortality (adjusted hazard ratio [aHR], 0.86), and lower prostate cancer-specific mortality (aHR, 0.83). The strongest inverse associations between PSA screening prevalence and advanced cancer were seen among men of Hispanic ethnicity (aOR, 0.82), older men (aged ≥70 years: aOR, 0.77), and those in the Northeast (aOR, 0.81). The strongest inverse associations with all-cause mortality were seen among men of Hispanic ethnicity (aHR, 0.82), younger versus older men (aHR, 0.81), those with advanced versus localized disease (aHR, 0.80), and those in the West (aHR, 0.89).
"Associations varied based on sociodemographic and geographic characteristics, supporting calls for tailored screening recommendations in population subgroups with a higher risk of aggressive disease," the authors write.
One author disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2024
Read this next
Rare Predicted Loss-of-Function Variants, Polygenic Risk Score Linked to Risk of A-Fib
THURSDAY, June 27, 2024 -- Rare predicted loss-of-function (pLOF) variants and a polygenic risk score (PRS) are associated with increased atrial fibrillation (AF) risk, according...
Lower Risk of ALS Seen for Men With High Levels of Physical Activity, Fitness
WEDNESDAY, June 26, 2024 -- For men, high levels of physical activity and fitness are associated with reduced risk of amyotrophic lateral sclerosis (ALS), according to a study...
Glofitamab + GemOx Superior to Rituximab + GemOx for Lymphoma
WEDNESDAY, June 26, 2024 -- Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.